Btc Health (ASX: BTC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Btc Health Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Btc Health (ASX: BTC)
Latest News
⏸️ Investing
6 listed funds with tax free capital gains and dividends
BTC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Btc Health
BTC Health Ltd. is a pooled development fund, which makes and manages investments in healthcare ventures. The firm makes active investments in businesses that acquire, develop and distribute medical products in Australia and New Zealand. The company was founded on March 14, 2000 and is headquartered in Hawthorn, Australia.
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 24 Jun 2025 | Richard Treagus | Buy | 319,939 | $16,636 |
On-market trade.
|
| 24 Jun 2025 | Martin Kahanovitz | Buy | 3,850,000 | $200,200 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr Richard Spencer Treagus | Executive ChairmanExecutive Director | Aug 2014 |
Dr Treagus is an entrepreneur with over 25 years' experience in all aspects of the international pharmaceutical and biotechnology industry. Formerly a Director of Neuren Pharmaceuticals Limited.
|
| Ms Felicity McNeill | Non-Executive Director | Oct 2022 |
Ms. McNeill is a senior executive with 25 years' experience across the public and private sector including almost 15 years in the regulatory and subsidy systems for medicines, vaccines, devices and diagnostics in Australia. Appointed 10 October 2022.
|
| Mr Martin Kahanovitz | Non-Executive Director | Jun 2025 |
Mr Kahanovitz is Chief Financial Officer of the Kahma Healthcare Group and also serves as Director for The Biologicals and Vaccine Institute of Southern Africa (Pty) Ltd t/a Biovac and as Chairperson for the Finance and Risk Board Committee. Mr. Kahanovitz is a registered Director with nearly 30 years of professional experience in the biotechnology, pharmaceutical, and medical industries.
|
| Mr Salesh Balak | Chief Financial OfficerCompany Secretary | Mar 2025 |
-
|
| Salesh Balak | Chief Financial OfficerCompany Secretary |
-
|
|
| J Kahanovitz | Chief Operating Officer |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| J P Morgan Nominees Australia Pty Limited | 93,087,758 | 28.61% |
| Mrs Karen Elizabeth Treagus | 30,000,000 | 9.22% |
| Sigma Company Limited | 16,856,467 | 5.18% |
| Namarong Investments Pty Ltd | 15,000,000 | 4.61% |
| Glk Medical Pty Ltd | 14,092,318 | 4.33% |
| Kingfisher Medical Pty Ltd | 14,092,318 | 4.33% |
| Tau Investments Australia Pty Ltd | 14,092,318 | 4.33% |
| Mr Thomas Christopher Fennell | 8,682,787 | 2.67% |
| Sigma Company Limited i | 8,143,533 | 2.50% |
| Mr Campbell Dinwoodie Taylor | 7,985,024 | 2.45% |
| Argus Nominees Pty Ltd | 5,500,000 | 1.69% |
| Mrs Susan Maree Whiting | 5,000,000 | 1.54% |
| Windarri Investments Pty Ltd | 4,213,727 | 1.30% |
| HSBC Custody Nominees (Australia) Limited | 4,206,000 | 1.29% |
| Mr Nicholas Dermott Mcdonald | 4,204,791 | 1.29% |
| Mr Martin Michael Kahanovitz | 3,850,000 | 1.18% |
| Abeille Investments Pty Limited | 3,800,000 | 1.17% |
| Sigma Company Limited ii | 3,627,553 | 1.12% |
| Namarong Investments Pty Ltd i | 3,125,000 | 0.96% |
| Linwierik Investments Pty Ltd | 2,600,000 | 0.80% |
| Chanuk Nominees Pty Ltd | 2,000,000 | 0.61% |
| Pritdown Pty Ltd | 2,000,000 | 0.61% |
| Mr Oskar Hakansson | 1,798,758 | 0.55% |
